Amarin Co. plc (AMRN) Insider Sells $284,605.20 in Stock

Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 64,683 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $4.40, for a total transaction of $284,605.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Amarin Co. plc (NASDAQ:AMRN) traded down $0.04 during midday trading on Friday, reaching $3.76. 3,208,393 shares of the company’s stock were exchanged, compared to its average volume of 2,620,000. The firm has a market capitalization of $1,010.00, a PE ratio of -13.91 and a beta of 0.50. Amarin Co. plc has a 52 week low of $2.85 and a 52 week high of $4.60. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. The firm’s revenue for the quarter was up 45.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.08) EPS. equities research analysts anticipate that Amarin Co. plc will post -0.22 EPS for the current fiscal year.

Several research analysts have recently weighed in on AMRN shares. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the company a “buy” rating in a research report on Wednesday, December 6th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Amarin in a research report on Thursday, November 2nd. Jefferies Group reaffirmed a “buy” rating on shares of Amarin in a research report on Wednesday, October 11th. BidaskClub raised shares of Amarin from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Finally, ValuEngine raised shares of Amarin from a “sell” rating to a “hold” rating in a research report on Saturday, November 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.75.

Institutional investors and hedge funds have recently modified their holdings of the company. Westside Investment Management Inc. lifted its position in shares of Amarin by 1.1% during the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 300 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Amarin by 15.2% during the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 5,000 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Amarin during the third quarter worth about $226,000. Stevens Capital Management LP acquired a new stake in shares of Amarin during the third quarter worth about $229,000. Finally, TD Asset Management Inc. acquired a new stake in shares of Amarin during the third quarter worth about $285,000. 40.14% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/03/insider-selling-amarin-co-plc-amrn-insider-sells-284605-20-in-stock.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply